SINGAPORE, Jan. 07, 2026 — Boyang Wang, founder of the Singapore-based longevity investment firm Immortal Dragons, has released a public statement after taking part in a recent installment of the Financial Times’ technology podcast, Tech Tonic, called “Defying Death: The Longevity Lab.”
The episode explores Singapore’s rise as a worldwide center for longevity R&D, underscoring the nation’s strategic emphasis on healthspan, its advanced biomedical research facilities, and regulatory systems that encourage experimental science. Wang contributed to the discussion by analyzing the investment and regulatory forces influencing Asia’s longevity industry.
Following the podcast’s publication, Wang commented that the conversation illustrates wider international changes in the funding, governance, and pursuit of longevity research.
“Singapore embodies a distinctive blend of capital, expertise, and practical regulation,” Wang stated. “With populations aging globally, the central issue has shifted from if longevity research will grow to where it can be developed responsibly and on a large scale.”
In the podcast, Wang elaborated on how varying regulatory landscapes affect the viability of early-stage biomedical studies. He pointed out that specific preclinical research, particularly involving advanced animal models, encounters much greater obstacles in Western countries, frequently demanding lengthy approval processes and significant funding. Wang indicated that some Asian regions offer different routes that permit investigative research while still adhering to legal and institutional guidelines.
Wang also commented on the theoretical aspect of certain longevity concepts covered in the episode, stressing that these should be viewed as long-horizon scientific inquiry, not imminent medical treatments. He recognized that achieving scientific agreement and clinical proof are vital parts of ethical innovation.
The podcast also included views from medical experts who warned about the risks of early commercialization and the lack of uniform biomarkers in the longevity field. Wang expressed support for this oversight, noting that public discourse and rigorous analysis are crucial as the sector advances.
“Longevity science is transitioning from a niche interest to a mainstream pursuit,” Wang remarked. “This shift demands openness, educated conversation, and distinct lines separating research, theory, and practical medical use.”
The Tech Tonic episode presents Singapore as an example of how government strategy, venture capital, and demographic trends combine to influence the direction of aging research. Wang’s involvement highlights the increasing significance of private investment in funding initial scientific exploration in partnership with public bodies.
The episode “Defying Death: The Longevity Lab” is currently accessible through the Tech Tonic podcast series.
About Immortal Dragons
Immortal Dragons is a purpose-led longevity investment fund based in Singapore, concentrating on high-potential, early-stage technologies designed to extend human healthspan. The fund presently backs over 15 portfolio companies working in various fields of longevity science and biotechnology. Beyond investing, Immortal Dragons advances longevity education and awareness by translating and publishing books, interpreting talks from international longevity figures, producing a prominent Chinese-language longevity podcast, and offering sponsorships and grants for longevity-centric projects and conferences.
Contact
Boyang Wang
press@id.life
A photo accompanying this announcement is available at
